Current and Emerging First-line Therapies in Renal Clear-cell Cancer

Rapidly evolving landscape in renal cell cancer
 
 
LAP Lambert Academic Publishing
  • erschienen am 20. November 2019
 
  • Buch
  • |
  • Softcover
  • |
  • 52 Seiten
978-620-0-46311-1 (ISBN)
 
Currently, 7 targeted agents and the combination of nivolumab/ipilimumab have been approved as first-line therapy for mccRCC. Sunitinib and pazopanib are the most effective first-line options, especially in favorable- and indermediate-risk patients. Nivolumab/ipilimumab seem to be the preferred first-line therapy in poor-risk patients, although cabozantinib, temsirolimus, sunitinib and pazopanib are also recommended. HD IL-2 remains a reasonable first-line treatment option in selected, favorable-risk younger patients with good performance status. The combination of ICI/VEGF-TKI is currently underway. Combinations of pembrolizumab/axitinib, avelumab/axitinib, atezolizumab/bevacizumab and pembrolizumab/lenvatinib seem to introduce the mccRCC therapy in a new auspicious era.
  • Englisch
  • Höhe: 220 mm
  • |
  • Breite: 150 mm
  • |
  • Dicke: 3 mm
  • 96 gr
978-620-0-46311-1 (9786200463111)
Dr Theodoros Tegos holds a PhD degree on "First-line therapies in metastatic clear-renal cell carcinoma". Currently he is working in the Oncological Department of the Evangelismos General Hospital in Athens, Greece. His specialty is Oncology.

Sofort lieferbar

26,90 €
inkl. 7% MwSt.
in den Warenkorb